drugset
drugset / Trial / NCT04155424

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

NCT04155424 ↗

Phase 2/3 Terminated 5 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to \< 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Timeline

Start
2020-01-14
Primary completion
2023-07-31
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody — Intravenous

Indications

neuromyelitis optica